Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Bioorganic & medicinal chemistry letters - 1 Mar 2010

Coughlin John E, Padmanabhan Seetharamaiyer, Zhang Guangrong, Kirk Cassandra J, Govardhan Chandrika P, Korba Brent E, O'Loughlin Kathleen, Green Carol E, Mirsalis Jon, Morrey John D, Iyer Radhakrishnan P

Abstract excerpt

The acyloxyalkyl derivatives of a model anti-HBV dinucleotide were synthesized and evaluated as orally bioavailable prodrugs. Our studies have led to the identification of the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents
Share to Hepatitis B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Mice, Transgenic

Share to Nucleotides

Share to Prodrugs

Share to Rats, Sprague-Dawley

Source

Open in PubMed Open full text

Identifiers

PMID: 20117930
DOI: 10.1016/j.bmcl.2010.01.010
PMCID: PMC2826611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20117930-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.PMID 20117930Read ↗

Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.Semantic proximity Read ↗

Prediction of Transporter-Mediated Drug-Drug Interactions and Phenotyping of Hepatobiliary Transporters Involved in the Clearance of E7766, a Novel Macrocycle-Bridged Dinucleotide.Semantic proximity Read ↗

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.Semantic proximity Read ↗

Nucleotide Prodrugs for HCV TherapySemantic proximity Read ↗

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria ChemoprotectionSemantic proximity Read ↗

Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.Semantic proximity Read ↗

Cytomegalovirus protease targeted prodrug development.Semantic proximity Read ↗

2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants.Semantic proximity Read ↗

Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620Semantic proximity Read ↗

Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.Semantic proximity Read ↗

"Lock-in" modified cyclosal nucleotides--the second generation of cyclosal prodrugs.Semantic proximity Read ↗

Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.